Skip to main content
. 2016 Feb 12;7(10):11708–11723. doi: 10.18632/oncotarget.7336

Figure 1. Increased nuclear pSTAT3 expression in human pancreatic adenocarcinoma is associated with poor clinical outcome.

Figure 1

(A) Representative images of pSTAT3 immunohistochemistry staining in pancreatic tissues (Bar: 100.8 μm. Magnification: 400×). Black arrows highlight positive staining. (B) Percentage of nuclear pSTAT3 expression in non-neoplastic tissue and PDCA. *The percentage of high nuclear pSTAT3 in chronic pancreatitis and pancreatic cancer was compared to that of normal pancreas. aThe percentage of high nuclear pSTAT3 in pancreatic cancer was compared to that of chronic pancreatitis. Chi-square test. (C) Kaplan-Meier analysis of the overall survival of 60 patients comparing high and low nuclear pSTAT3. Patients with high pSTAT3 have a shorter medium survival comparing to those with low pSTAT3 (13 months vs 30 months, P = 0.207, log-rank test). (D) Nuclear pSTAT3 expression in pancreatic tissues with low grade or high grade. Patients with high grade tumors (III, n = 37) have higher nuclear pSTAT3 expression compared to those with low grade tumors (I + II, n = 119) (p = 0.0259, t-test).